Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-SAB: Sotorasib and SBRT in Advanced KRAS G12C NSCLC
NCT06127940Phase 1Recruiting
- Sponsor
- Karolinska University Hospital
- Start
- Oct 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of sotorasib, sponsored by Karolinska University Hospital. Primary endpoint: Grade 3-5 toxicity attributed to SBRT at 6 months. Started Oct 2023; status: recruiting.
02
Drugs
sotorasib
Beyond the preview
Go deeper on NCT06127940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06127940.